Stay updated on ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC
Sign up to get notified when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.
Latest updates to the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 22 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.0%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.SummaryDifference0.0%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Breast cancer MedlinePlus related topics: Breast Cancer Drug Information available for: Eribulin Eribulin mesylate Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Eribulin Mesylate + Pembrolizumab Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting. Drug : Eribulin Mesylate Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent. Other Names: Halaven, E7389 Drug : Pembrolizumab Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent. Other Names: Keytruda, MK-3475SummaryDifference76%
Stay in the know with updates to ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC
Enter your email address, and we'll notify you when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.